Recursion Reports First Quarter Financial Results and Provides Business Update
Recursion reported Q1 2026 revenue of $6.5 million, down from $14.7 million in the prior year due to the completion of specific Roche project phases. Despite the revenue decline, the company significantly narrowed its net loss to $117.5 million from $202.5 million, driven by improved operational efficiency and reduced R&D expenses.
Key figures
- Revenue
- 6472000
- Guidance
- <$390 million operational cash burn for 2026
- Net loss
- 117500000
- Rd expenses
- 87900000
- Cash position
- 665200000
- Cash operating expense
- 85100000
- Partner milestones to date
- 500000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.